Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Complete title: A Pilot Study of Pembrolizumab in Combination with Y90 Radioembolization in Subjects with Poor Prognosis Hepatocellular Carcinoma with Preserved Liver Function

Research Study Number 9913
Principal Investigator William Harris
Phase Pilot

Research Study Description

This is an open-label multi-center trial designed to evaluate the efficacy as well as the safety of combining pembrolizumab with Yttrium-90 (Y90) radioembolization in subjects with poor prognosis (high risk) HCC not eligible for liver transplant or surgical resection with well compensated liver function. Treatment will consist of pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization performed one week after the first dose of pembrolizumab. If bilobar disease is present, a second Y90 radioembolization will be performed no later than 4 weeks after the first procedure to the contralateral hepatic lobe.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 9913
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Liver Cancer; Solid Tumors; Digestive System Neoplasms; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma, Hepatocellular; Digestive System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials